To the Editor: We report the occurrence of acute pancreatitisin children being treated with recombinant growth hormone forshort stature.
The index patient was a 12-year-old boy with pseudohypoparathyroidismwho was receiving thyroxine and vitamin D. The patient was shortand had biochemical evidence of growth hormone deficiency, forwhich he was treated with growth hormone at a dose of 0.05 mgper kilogram of body weight per day. After the sixth dose, nausea,vomiting, and severe abdominal pain developed in the absenceof prodromal symptoms of infection or any history of abdominaltrauma. When admitted to the hospital, . . . [Full Text of this Article]
References
This article has been cited by other articles:
Bolar, K., Hoffman, A. R., Maneatis, T., Lippe, B.
(2008). Long-Term Safety of Recombinant Human Growth Hormone in Turner Syndrome. J. Clin. Endocrinol. Metab.
93: 344-351
[Abstract][Full Text]
Bravo, E. L., Tagle, R.
(2003). Pheochromocytoma: State-of-the-Art and Future Prospects. Endocr. Rev.
24: 539-553
[Abstract][Full Text]
Eisenhofer, G., Goldstein, D. S., Walther, M. M., Friberg, P., Lenders, J. W. M., Keiser, H. R., Pacak, K.
(2003). Biochemical Diagnosis of Pheochromocytoma: How to Distinguish True- from False-Positive Test Results. J. Clin. Endocrinol. Metab.
88: 2656-2666
[Abstract][Full Text]
Campbell, E. G., Weissman, J. S., Blumenthal, D.
(1997). Relationship Between Market Competition and the Activities and Attitudes of Medical School Faculty. JAMA
278: 222-226
[Abstract]